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Abstract
Background: Composite measures combine data to provide a comprehensive view of patient outcomes. Despite
composite measures being a valuable tool to assess post-intervention outcomes, the patient perspective is often
missing. The purpose of this study was to develop a composite measure for an established cardiac outcome
registry, by combining clinical outcomes following percutaneous coronary interventions (PCI) with a patient-
reported outcome measure (PROM) developed specifically for this population (MC-PROM).
Methods: Two studies were undertaken. Study 1: Patients who had undergone a PCI at one of the three participating
registry hospital sites completed the 5-item MC-PROM. Clinical outcome data for the patients (e.g. death, myocardial
infarction, repeat vascularisation, new bleeding event) were collected 30 days post-intervention as part of routine data
collection for the cardiac registry. Exploratory factor analysis of clinical outcomes and MC-PROM data was conducted to
determine the minimum number of constructs to be included in a composite measure. Study 2: Clinical experts
participated in a Delphi technique, consisting of three rounds of online surveys, to determine the clinical outcomes to
be included and the weighting of the clinical outcomes and MC-PROM score for the composite measure.
Results: Study 1: Routine clinical outcomes and the MC-PROM data were collected from 266 patients 30 days post PCI.
The MC-PROM score was not significantly correlated with any clinical outcomes.
Study 2: There was a relatively consistent approach to the weighting of the clinical outcomes and MC-PROM items by
the expert panel (n = 18) across the three surveys with the exception of the clinical outcome of ‘deceased at 30 days’.
The final composite measure included five clinical outcomes within 30 days weighted at 90% (new heart failure, new
myocardial infarction, new stent thrombosis, major bleeding event, new stroke, unplanned cardiac rehospitalisation)
and the MC-PROM score (comprising 10% of the total weighting).
Conclusions: A single patient level composite score, which incorporates weighted clinical outcomes and a PROM was
developed. This composite score provides a more comprehensive reported measure of individual patient wellbeing at
30 days post their PCI-procedure, and may assist clinicians to further assess and address patient level factors that
potentially impact on clinical recovery.
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Background
As a result of advances in interventions, mortality rates in
cardiac patients have declined over the past decades and
more people live longer with heart disease [1]. These pa-
tients are at high risk of experiencing a recurrent cardiac
event and the focus is now on optimising the quality of
secondary preventive care [2]. In a scientific statement,
the American Heart Association states that implementa-
tion of patient reported outcome measures (PROMs) in
clinical settings has “the potential to support clinical care,
evaluate healthcare quality, quantify an important compo-
nent of procedural appropriateness, identify patients for
prognostic discussions and serve as a foundation for
shared medical decision making” [3]. In surveillance,
PROMs have the potential to quantify the impact of the
disease as well as of the therapies and interventions for
these conditions on patients’ lives [3].
Clinical quality registries (CQR) systematically monitor
the quality of health care within specific clinical domains
by routinely collecting, analysing and reporting health-
related information [4]. The increasing number of CQRs
is in large part due to their unique ability to provide cli-
nicians and administrators with regular feedback about
clinical performance (including outcomes) that cannot
be provided by other strategies such as individual hos-
pital datasets. The information that CQRs generate is
respected by clinicians and has the credibility to drive
change. In doing so, registries complement a variety of
other approaches to clinical quality improvement such
as sentinel event reporting, limited adverse occurrence
screening, incident reporting, morbidity and mortality
reviews and patient satisfaction surveys [5–7]. By imple-
menting PROMs, registries can provide a more compre-
hensive measure of procedure outcomes and contribute
to surveillance, enable benchmarking and drive quality
improvement of health care services [8].
Composite measures for reporting outcomes
A composite measure is a summary variable created by
grouping two or more outcomes which are related to
one another conceptually or statistically [9]. Composite
measures facilitate benchmarking performance and en-
courage quality improvement initiatives across various
industry sectors and organisations [10, 11]. Composite
measures assist in health related decision making, evalu-
ation of an individual’s health outcomes, and assessment
of standards, performance and quality of care across dif-
ferent health sectors [12–16]. Composite measures may
also be easier for clinicians to operationalise as they cap-
ture both the good and poor outcomes of care in one
measure.
Composite measures have typically been derived from
combining clinical outcomes, with a focus on clinician
and healthcare facility performance as an outcome. For
example, the Coronary Artery Bypass Graft (CABG)
Composite Score from the Society of Thoracic Surgeons
CABG registry is calculated using a combination of 11
clinical outcomes. The composite score is divided into
four domains: mortality, morbidity, use of internal mam-
mary artery, and perioperative medication [17]. This
score provides an indicator of surgeon performance.
Missing from this measure, and other cardiac outcome
composite measures, is the patients’ perspective of re-
covery that incorporates quality of life and functioning
post-procedure, which may be predictive of longer-term
clinical outcomes [2]. Patient pathways following percu-
taneous coronary intervention (PCI) have traditionally
focused on treatment efficacy and safety, with a conse-
quent lack of emphasis on PROMs in recent PCI and
Acute Coronary Syndrome (ACS) guidelines.. As an ex-
ample, the most recent Australian ACS guidelines does
not list a patient reported outcome measure (PROM) in
the section on Measures of Performance and Clinical
Standards [18].
The Victorian Cardiac Outcomes Registry (VCOR) is a
CQR that provides performance outcomes for PCI at a
health service level. The registry incorporates all 31 hos-
pitals that perform PCI in the state of Victoria, Australia
and is now well-established, with five years of data col-
lection and over 40,000 case records. From 2019, VCOR
will provide benchmarked reports to the Victorian De-
partment of Health and Human Services to include in
their state-wide quality reporting framework.
A PROM has been developed for use by VCOR to as-
sess recovery following PCI at 30 days post procedure
[19–21]. The Monash University Cardiac PROM (MC-
PROM) was developed via a three-stage research project
that involved patients in every aspect. Stage one con-
sisted of focus groups and interviews with 32 patients
who had a PCI in the preceding six months. Patients
were asked to identify physical, psychological and func-
tional outcomes they perceived as important in terms of
recovery from their PCI [19]. Based on this stage, 10
outcomes were identified. In stage two, a discrete choice
experiment survey with 138 patients within six months
of their PCI was conducted to establish patient prefer-
ences for the 10 outcomes. The perceived important PCI
outcomes were reduced to eight after this stage [20].
The final stage was to identify and validate the best set
of items to form a concise and psychometrically sound
PROM using Rasch analysis. A consecutive sample of
200 patients participated in a telephone survey 30 days
following their PCI procedure. Five items were identified
that can be included in a PROM post-PCI (Fig. 1). The
MC-PROM was found to have good internal construct
validity and acceptable internal consistency reliability
[21]. We found evidence to sum scores from each item
to obtain an overall score scored out of 10, with lower
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scores indicating better patient recovery [21]. The MC-
PROM was also found to have a moderately strong and
negative correlation with the EQ-5D utility score (Spear-
man’s rho − 0.53; p < 0.01).
The aim of this project was to develop a composite
measure that combines clinical outcomes with the MC-
PROM to measure the quality of PCI at 30 days in a car-
diac registry. The specific objectives were to:
1. Determine the minimum number of clinical
outcomes to be included in the composite measure;
2. Assign weightings to the outcomes in the
composite measure; and,
3. Propose possible end points for the future
validation of the composite measure.
Methods
This project consisted of two studies (Fig. 2) to address
the objectives described above.
Study 1: factor analysis of MC-PROM and clinical
outcomes
This study was designed to address objective 1 – to de-
termine the minimum number of clinical outcomes to
include in the composite measure.
Fig. 1 MC-PROM
Fig. 2 Overview of project studies
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Participants
Three tertiary public hospitals in metropolitan Victoria,
Australia that have contributed to VCOR since 2013
were invited to participate in this study. The hospitals
ranged in size from moderate (400–600 beds) to large
(> 600 beds). Patients who were 18 years of age or older,
and had a PCI at any of these participating hospitals
were invited to complete the MC-PROM during their
30-day follow-up (administered via telephone) by the
hospital between September 2017 and February 2018.
Verbal consent was obtained from patients. The follow-
ing script was administered by the facility VCOR data
managers: “We are trialling some new questions to find
out about your health and wellbeing following your PCI.
These questions were developed by patients and re-
searchers. I will ask you five questions that relate to how
you have felt in the last seven days. Are you happy for
me to ask you these questions?” If the patient declined,
the data manager did not ask the PROM questions.
Data collection
Participating patients were asked to provide responses to
the MC-PROM by the VCOR data manager during their
routine 30-day follow up phone call. Demographic infor-
mation and data regarding the seven clinical outcomes
were obtained from data routinely collected by VCOR
that is collected and managed using REDCap electronic
data capture tools hosted at Monash University [22].
Data collection was from the 10th of September 2017 to
the 15th of February 2018.
Data analysis
Descriptive statistics were used to profile the cohort, the
clinical outcomes and MC-PROM data collected by
VCOR. Exploratory analysis was conducted to determine
the minimum number of constructs that could be in-
cluded in a composite measure for patients following a
PCI. Principal component analysis was used to extract
the factors and explore the underlying structure of the
composite measure. The Kaiser’s criterion, where all
outcomes with an eigenvalue of 1 or more, in conjunc-
tion with the Scree test, determined the number of out-
comes (factors or dimensions) to be retained. Factor
loadings were also used to weight the different clinical
outcomes. There is no standard method for estimating
sample size in factor analysis, although it is generally
recommended that the number of observations is
dependent on the number of outcomes that will be ex-
amined in the model. Traditional recommendations
within psychometrics is to include at least 10 to 20 cases
per variable to allow significant testing of model effects
[23]. We anticipated that the composite measure would
include 8–10 outcomes when combining the available
clinical indicators with the MC-PROM, hence a sample
size of between 80 to 160 participants was required for
this analysis. All statistical analyses were conducted
using SPSS Version 25 (IBM Corp, IBM Statistics for
Windows. Armonk, NY: IBM Corp).
Study 2: modified Delphi to determine the weighting of
the factors in the composite measure and possible end
points for future validation studies
This study was designed to address objectives 2 and 3:
2. Assign weightings to the outcomes in the
composite measure; and,
3. Propose possible end points for the future
validation of the composite measure.
Participants
Convenience and purposive sampling (to ensure a mix of
metropolitan and regional, and public and private settings)
was adopted to recruit clinical experts to the Delphi study.
The Clinical Director (author JL) invited cardiac clinicians,
nurses, VCOR representatives and health service man-
agers to participate in the Delphi. As the final composite
measure will be used by VCOR and cardiac clinical ex-
perts, participants for this study focused on ensuring rep-
resentation from this group. Invitations to participate
were sent via the VCOR clinical director as a personal
email with a survey link. Consent was implied by survey
completion. The surveys were hosted online via the survey
platform Qualtrics (Qualtrics, 2018). To maintain the con-
fidentiality of the participants, no demographic or profes-
sional information was collected in the survey.
Data collection
In the first round, participants had two tasks. First they
were asked to rate the importance of each of the seven
clinical outcomes (Table 1) and the MC-PROM items
on a scale of 1 to 9 (9 = highly important, 1 = not im-
portant) based on whether it represents quality of care.
Participants were asked to provide a rationale for their
rating.
For the second task, participants were provided with a
list of proposed endpoints (e.g. all-cause mortality at 6
months, major adverse cardiac and cerebrovascular
events (MAACE) at 12 months), identified from the lit-
erature and clinical experts, that could be used to valid-
ate the composite measure to predict patient recovery
post PCI in future research. Participants were asked to
rank from 1 (most important) to 8 (least important) the
suggested endpoints and nominate any additional end-
points to consider. The first round survey was open
from the 22nd of November 2017 to the 3rd of Decem-
ber 2017.
The second round of the Delphi invited the same ex-
perts from Round 1 to participate. Participants were
Ayton et al. BMC Health Services Research           (2020) 20:44 Page 4 of 11
presented with the median scores and summarised ratio-
nales for each of the clinical outcomes rated in Round 1.
Based on this information, participants were asked to re-
rate each of the clinical outcomes. Participants were also
presented for the first time with the findings from the
analysis of patient data (MC-PROM and clinical out-
comes) from study 1, and asked about inclusion of po-
tentially correlated clinical outcomes. They were then
asked to assign a percentage weight for each of the pro-
posed clinical outcomes and the MC-PROM summary
score for inclusion in the composite measure. The
weightings for all the outcomes needed to add up to
100%. The second round survey was open from the 26th
of April to the 8th of June 2018.
The third and final round of the Delphi invited the
same experts to participate. Participants were presented
with the aggregated results of the Round 2 weightings,
two proposed composite measure models, as well as ex-
amples of how the composite measure would be calcu-
lated. The third round survey was open from the 28th of
June 2018 to the 18th of the July 2018.
Data analysis
At the end of the round one Delphi survey, the median
and interquartile range of the rating of importance for
each of the seven clinical outcomes was calculated. Free
text comments in relation to the rationale for prioritisa-
tion of each of the clinical outcomes were summarised
thematically. The mean and median rankings of sug-
gested endpoints for the validation of the composite
measure was also calculated.
For round two of the Delphi survey, the median and
interquartile range of importance rating for each clinical
outcome was recalculated. Additionally, the findings
from the analysis of the patient outcomes from compo-
nent 1 were summarised. Thirdly, the median of the pro-
posed weightings were calculated for the clinical
outcomes and the MC-PROM data. For the weightings,
the median was recalculated so that the sum of the out-
comes equalled 100.
At the conclusion of the third round, the data analysis
allowed the creation of a model of a single composite
measure that included both prioritised clinical outcomes
and the MC-PROM, weighted by the expert panel as to
each outcomes relative importance. All statistical analyses
were conducted using SPSS Version 25.0 (IBM Corp, IBM
Statistics for Windows. Armonk, NY: IBM Corp).
Scoring the composite measure
After the creation of a composite measure model, a scor-
ing framework was developed. Positive scoring was used
so that a higher score reflected a better patient outcome.
Therefore, if an identified (adverse) clinical outcome oc-
curred, a zero was assigned; and if an identified clinical
outcome was not present, a ‘one’ was assigned. The clin-
ical outcome was then multiplied by the median weight-
ing to create its component of the composite measure.
Box 1 outlines the calculation for including the overall
MC-PROM score and the individual clinical outcomes
in the composite measure. The weighted scores for the
MC-PROM and each clinical outcome were summed to
provide an overall composite score. The composite
measure is scored out of 100. A higher score indicates
better health and wellbeing for the patient; a lower score
indicates poorer health and wellbeing for the patient
(Fig. 3).
Ethics approval for this project was obtained from
Monash University Human Research Ethics Committee
and the respective hospital ethics committees.
Results
Study 1:factor analysis of MC-PROM and clinical outcomes
routinely collected in VCOR
Participants
The MC-PROM was administered to 266 patients who
had undergone a PCI at one of the participating hospi-
tals during their routine 30-day follow-up phone call
with VCOR. No patient declined to complete the MC-
PROM. Table 1 presents the patient characteristics in-
cluding the clinical outcomes and mean overall MC-
PROM score. The composition of our study sample was
broadly similar to the overall VCOR patient cohort and
Table 1 Characteristics of patients following PCI procedure
Patients in this study
(n = 266)
Male, n (%) 212 (79.7)
Age, mean (SD) 64.3 (11.0)
Clinical presentation, n (%)
STEMI 95 (35.7)
NSTE-ACS 99 (37.2)
Non-ACS 72 (27.1)
Clinical outcomes at 30 days, n (%)
Deceased 0 (0)
New heart failure 1 (0.4)
New myocardial infarction 0 (0)
New stent thrombosis 0 (0)
New stroke 0 (0)
New bleeding event 37 (14.0)
Unplanned cardiac rehospitalisation 3 (1.1)
PCI-specific PROM, mean (SD)
Overall score 7.6 (2.0)
STEMI ST-Elevation Myocardial Infarction, NSTE-ACS Non-ST-segment-elevation
acute coronary syndrome, Non-ACS Non-acute coronary syndrome, CABG
Coronary artery bypass grafting, PCI Percutaneous Coronary Intervention,
PROM Patient Reported Outcome Measure
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with the British NICOR-BCIS Audit of Percutaneous
Coronary Interventions [24] . There was a predominance
of males (80% our study, 76% VCOR cohort), with simi-
lar mean ages (64 years our study, 66 years VCOR co-
hort). However, there were some differences in relation
to clinical presentation between the two groups. In our
study, 73% of patients presented with an ACS, with a
near-even split between acute ST elevation myocardial
infarction (STEMI) (36%) and non-ST elevation ACS
(37%). The VCOR cohort had a lower proportion of pa-
tients with ACS (53%), 21% with STEMI and 30% with
non-ST elevation ACS [25]. None of our participants
died at 30 days, and only 16% of participants (n = 41) re-
ported experiencing a clinical outcome post-procedure.
This is consistent with the overall VCOR patient cohort
where the rates of any of these outcomes range from 0.4
to 13.7% [25].
Exploratory factor analysis
The clinical outcomes and MC-PROM data were
subjected to principal component analysis. Prior to per-
forming the principal component analysis, the suitability
of data for factor analysis was assessed. Inspection of the
correlation matrix (Table 2) revealed that only two out-
comes, unplanned cardiac rehospitalisation and new
heart failure within 30 days following PCI, demonstrated
a moderate association (r = 0.58). A factor analysis was
therefore not appropriate, and factor loadings were not
obtained.
Weak associations were observed between the over-
all MC-PROM score and new heart failure (r = 0.04),
new bleeding event (r = 0.02) and unplanned cardiac
rehospitalisation (r = 0.10). Further analysis with
Mann-Whitney U tests, however, revealed no signifi-
cant differences between the overall MC-PROM
median scores and the clinical outcomes at 30 days
post-procedure. The potential correlation between
unplanned cardiac rehospitalisation and new heart
failure was included as a choice question in Round 2
of the Delphi survey in order to determine clinical
experts’ opinion about which outcome should be
included in the composite measure.
Study 2: modified Delphi to determine the weighting of
the factors in the composite measure
Participants
Thirty-two clinical experts were invited to participate in
the Delphi surveys. The response rate for the first round
was 56% with 18 clinical experts completing the survey.
Invitations to participate in the later survey rounds were
only sent to the 18 clinical experts who participated in
round one. The response rate for round two and three
were 44% (n = 8) and 38% (n = 7) respectively.
Fig. 3 Composite Measure Calculation
Table 2 Correlation matrix for clinical outcomes and PCI-specific PROM
Deceased New heart
failure
New myocardial
infarction
New stent
thrombosis
New
bleeding
New
stroke
Unplanned cardiac
rehospitalisation
Overall
PROM score
Deceased 1.00 – – – – – – –
New heart failure – 1.00 – – −0.03 – 0.58 0.04
New myocardial
infarction
– – 1.00 – – – – –
New stent thrombosis – – – 1.00 – – – –
New bleeding – −0.03 – – 1.00 – 0.06 0.02
New stroke – – – – – 1.00 – –
Unplanned cardiac
rehospitalisation
– 0.58 – – 0.06 – 1.00 0.10
Overall PROM score – 0.04 – – 0.02 – 0.10 1.00
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Delphi expert survey Round 1.
Rating, inclusion and weighting of individual measures
in the composite measure The highest rated MC-PROM
item was ‘Pain or discomfort on exertion at 30 days
post-PCI’ (median = 9), and the lowest was ‘Trouble fall-
ing asleep or staying asleep at 30 days post-PCI’ (me-
dian = 5). Examples of rationales regarding the highest
and lowest rated MC-PROM items include, respectively,
“Chest pain and shortness of breath are key symptoms
that are hoped to be improved with stents” and “Many
patients have sleep problems!” The highest rated clinical
outcome was ‘new stent thrombosis within 30 days of
PCI’ (median rating = 9), and the lowest was ‘new heart
failure within 30 days of PCI’ (median = 6). Examples of
rationales regarding the highest and lowest rated clinical
outcome components include, respectively, “Very im-
portant as stent thrombosis is often due to technical PCI
factors or stent design so very clearly a marker of PCI
quality” and “PCI not directly related to heart failure oc-
currence - it can still occur even with successful PCI”.
Proposed endpoints for composite measure validation.
The highest rated endpoint was ‘mortality at 6 months’
(median ranking of 2) and the lowest rated endpoint was
‘rehospitalisation (any) at 6 months’ (median ranking of
7). Examples of rationales regarding the highest and low-
est ranked proposed endpoints include, respectively,
“Positive benefit on total mortality or MACCE at one
year seems a very hard endpoint” and “not a great be-
liever in re-hospitalisation as a hard endpoint that is
very relevant clinically”. The first six months post PCI
were considered an important endpoint for PCI related
adverse events: “First six months is critical post PCI re
adverse events. Beyond this other co morbidity factors
may well have greater significance. It is important to ap-
preciate both.” Other endpoints proposed by the expert
panel included: return to employment at six and 12
months; number of subsequent cardiac procedures; qual-
ity of life (QoL) assessment; aspirin and statin prescrip-
tion at 30 days; new diagnosis of depression or anxiety;
and, risk-adjusted mortality.
Round 2.
In Round 2, the highest rated clinical outcome was again
‘new stent thrombosis within 30 days of PCI’ (median rat-
ing = 9), and the lowest was again ‘new heart failure within
30 days of PCI’ (median = 6). Following the presentation
of the clinical outcome correlation results, four of the re-
spondents chose the option to ‘include unplanned cardiac
rehospitalisation only’ in the composite measure, while
four respondents chose the option to ‘include both un-
planned cardiac rehospitalisation and new heart failure’.
No respondents chose the option to ‘include new heart
failure only’. The MC-PROM score weighting ranged from
5 to 25%. The weightings of the clinical outcomes and
MC-PROM score are presented in Fig. 4.
The inclusion or exclusion of ‘deceased at 30 days’ from
the composite measure.
When calculating the composite score, the issue of
whether or not to include or exclude ‘deceased at 30
days’ was raised by investigators and the clinical experts.
The rationale for each argument is presented below:
1. Inclusion of ‘deceased at 30 days’: The median
weighting for ‘deceased within 30 days’ was 23%
(rating range 15–50%). None of the clinical experts
gave this indicator a weighting of zero or 100%.
Therefore it should be included in the composite
measure.
2. Exclusion of ‘deceased at 30 days’: Using the
proposed formula to calculate the composite
measure, a patient can be deceased within 30 days,
yet be able to achieve a relatively good composite
score. If the patient is deceased, they are unable to
complete the MC-PROM and therefore this score is
not able to be included in the composite measure.
Death is the ultimate negative outcome and there-
fore if a patient dies a zero should be awarded for
the composite measure.
The rationales above and example patient scenarios
were developed and presented to the clinical experts in
round 3.
Round 3.
In Round 3, the adjusted median of the weighted indi-
vidual clinical outcomes from Round 2 of the Delphi were
presented. Examples of patient scenarios were presented
with the calculated composite score (Table 3) and the ra-
tionales for including and excluding ‘deceased at 30 days’.
Two out of seven participants chose to include ‘deceased
at 30 days’ and five participants chose to exclude ‘deceased
at 30 days’ in the final composite measure. Four of the five
clinical experts re-weighted the MC-PROM score and
clinical outcomes based on removing ‘deceased at 30 days’.
The highest weighting was given to ‘new stent thrombosis
within 30 days of PCI’ (23%), and the lowest to ‘new heart
failure within 30 days of PCI’ (7%), while the ‘MC-PROM
score’ received a weighting of 10%. ‘Deceased at 30 days’
was excluded from the composite measure and the new
weightings applied. Example patient scenarios were calcu-
lated to demonstrate the composite measure scores across
different clinical outcomes and overall MC-PROM scores
(Table 3).
Discussion
In this study, we have developed a composite measure
that includes a PROM designed specifically for patients
following a PCI (MC-PROM) with objective clinical out-
comes. The implementation of PROMs in healthcare to
promote patient-centred care has been recognised as an
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international priority [3, 26]. However, the subjective na-
ture of PROMs does not always correspond to the clin-
ical outcome of the patient, while the objective nature of
the clinical outcome measures may not identify import-
ant barriers to patient recovery (e.g. confidence in carry-
ing out usual tasks). Additionally, through electronic
administrative data, audits and registries, a vast amount
of clinical outcome measures are available which can be
difficult to understand. A composite measure can con-
dense a number of outcome measures into a single score
which can simplify the data and provide an overview of
patient recovery and quality of care [27]. Combining
PROMs with objective clinical outcomes into a single
composite measure ensures that both the clinician and
patient perspectives are captured, providing an overview
of patient recovery and quality of care [27].
The relatively low final weighting of the MC-PROM
suggests that there may be an acceptability issue for cli-
nicians in relation to the use of a PROM as an outcome
measure, which is not uncommon [28, 29]. However, it
should be noted that some of the expert panel did
weight the MC-PROM at 25% of the composite measure
score. This indicates varying understanding and engage-
ment with the concept of PROMs by the panel mem-
bers. The aim of the MC-PROM was to provide an
indication of recovery for the patient in the context of a
CQR. Given that the vast majority of patients with PCI
do not experience a significant adverse clinical event, the
use of adverse outcomes as key clinical outcome mea-
sures by VCOR does not reflect the experience and
recovery of the majority of the registry population. Fur-
ther, experiences that many patients encounter post-PCI
procedure such as lack of confidence, anxiety/depres-
sion, and ongoing mild clinical symptoms, may not be
recognised or appropriately managed when they are not
incorporated within routine outcome measurement. This
composite measure approach seeks to provide a more
meaningful outcome measure for a majority of patients
during early recovery following their procedure. With in-
creasing use, and an increasing emphasis on PROMs in
CQRs [4], the acceptability of the MC-PROM in the
composite measure may increase.
A strength of this study was that the composite meas-
ure was developed using a multi-method approach that
included a factor analysis to determine the clinical PCI
outcomes that can be combined with the MC-PROM.
We then obtained a clinically meaningful weighting of
the clinical outcomes and PROM score identified in
Study 1 by undertaking three sequential Delphi surveys
with a recognised group of clinical experts. Thus, we
were able to develop a composite measure for patients
following PCI that combines clinically important indica-
tors as well as patient’s perspective of recovery. This
study represents methods that can be replicated in other
CQRs involving different patient populations and inter-
ventions to develop a composite measure. Additionally,
by involving clinical and registry experts, as well as
patients, to actively participate in the development of
the PROM and composite measure, there is validity and
acceptability for the final composite measure. Future
Fig. 4 Weighting of clinical outcomes and PROM score by clinical experts in round 2 and 3 of Delphi study
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validation studies of the PROM and engagement with
clinicians will be important to champion the use of the
PROM in the CQR and as part of a composite measure.
The endpoints proposed by the clinical experts can also
be used in future validation studies.
There are a number of limitations that need noting.
Firstly, there was a decrease in expert panel participa-
tion from Round 1 to 3 (from 18 to 7 survey comple-
tions). However, there was little change in the ratings
and weightings of the individual clinical outcome
measures, and the weighting of the PROM score, be-
tween rounds. We were also unable to complete a
factor analysis and obtain factor loadings because only
two outcomes demonstrated a moderate association.
This is likely due to the low number of participants
experiencing a cardiac event post intervention. Given
the low prevalence rates of these clinical outcomes
post-PCI, a larger sample should be considered when
planning future validation studies of the composite
measure. Nevertheless, it is important to keep in
mind that the prevalence rates observed in this study
is consistent with rates reported in VCOR [25] as
well as previous literature [30, 31]. Finally, patients
were not involved in the development of this compos-
ite measure and did not have an opportunity to
weight the PROM score with the clinical outcomes.
This composite measure is designed to be used by cli-
nicians and hence we focused on obtaining their in-
put. However it is important to note that patients
who have had a PCI were involved in each stage of
the development of the MC-PROM [19–21].
Conclusions
In this study we developed a composite measure that
combined the MC-PROM designed specifically for pa-
tients following a PCI with clinical outcomes to assess
recovery at 30 days. The MC-PROM was weighted at
10% of the overall composite measure with clinical out-
comes comprising the rest of the score. Utilising PROMs
in clinical registries to assess quality of care is gaining
traction internationally. Combining a PROM with clin-
ical outcomes to provide a composite measure of quality
of care in PCI is particularly important where adverse
clinical events (which are traditional clinical outcome
measures) are rare and may not be appropriate for asses-
sing quality of care for a majority of patients.
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